Ductal Carcinoma In Situ

Fang Meng Fu, Richard C. Gilmore, Lisa Jacobs

Research output: Contribution to journalReview article


Ductal carcinoma in situ has been stable in incidence for a decade and has an excellent prognosis. Breast conservation therapy is safe and effective for most patients. Adjuvant whole breast radiation therapy is recommended to reduce the risk of local recurrence. Accelerated partial breast irradiation is a promising alternative to decrease toxicity and improve cosmetic results. Adjuvant hormonal therapy can reduce local recurrence, but should be used cautiously. Future directions in management include developing predictive tools for guidance for use of adjuvant therapy and selecting low-risk patients with ductal carcinoma in situ in whom surgery may be safely omitted.

Original languageEnglish (US)
Pages (from-to)725-745
Number of pages21
JournalSurgical Clinics of North America
Issue number4
StatePublished - Aug 1 2018


  • Breast cancer
  • Ductal carcinoma in situ
  • Hormonal therapy
  • Incidence
  • Mortality
  • Radiation therapy

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Ductal Carcinoma In Situ'. Together they form a unique fingerprint.

  • Cite this